Cargando…
Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects
Mesenchymal stem cells (MSCs) are able to infiltrate tumor tissues and thereby effectively deliver gene therapeutic payloads. Here, we engineered murine MSCs (mMSCs) to express a secreted form of the TNF-related apoptosis-inducing ligand (TRAIL), which is a potent inducer of apoptosis in tumor cells...
Autores principales: | Yu, R, Deedigan, L, Albarenque, S M, Mohr, A, Zwacka, R M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734822/ https://www.ncbi.nlm.nih.gov/pubmed/23429289 http://dx.doi.org/10.1038/cddis.2013.19 |
Ejemplares similares
-
Assessment of concentrations of sTRAIL ligand and its receptors sTRAIL-R1 and sTRAIL-R2 – markers monitoring the course of the extrinsic pathway of apoptosis induction: potential application in ovarian cancer diagnostics
por: Mielczarek-Palacz, Aleksandra, et al.
Publicado: (2015) -
Engineered sTRAIL-armed MSCs overcome STING deficiency to enhance the therapeutic efficacy of radiotherapy for immune checkpoint blockade
por: Huang, Kevin Chih-Yang, et al.
Publicado: (2022) -
Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model
por: Mohr, Andrea, et al.
Publicado: (2008) -
sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment
por: Huang, Ying, et al.
Publicado: (2017) -
Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells
por: Bremer, Edwin, et al.
Publicado: (2008)